We have updated forecasts post H1 results (announced on 19th Sept), which highlighted a financial performance in line with our estimates and sales by product broadly in line with expectations (Silhouette Instalift™ slightly ahead; Sculptra® slightly below). We have left product-level forecasts broadly unchanged, with a downgrade to Sculptra® forecasts offset by higher expectations for Ellansé® following expected approval in Brazil in H1 2018. We continue to expect EBITDA profitability for FY2017 ....
16 Oct 2017
N+1 Singer - Sinclair Pharma - Forecast update; profitability inflection and strong growth ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Sinclair Pharma - Forecast update; profitability inflection and strong growth ahead
Sinclair Pharma (SPH:LON) | 0 0 0.6% | Mkt Cap: 111.5m
- Published:
16 Oct 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
We have updated forecasts post H1 results (announced on 19th Sept), which highlighted a financial performance in line with our estimates and sales by product broadly in line with expectations (Silhouette Instalift™ slightly ahead; Sculptra® slightly below). We have left product-level forecasts broadly unchanged, with a downgrade to Sculptra® forecasts offset by higher expectations for Ellansé® following expected approval in Brazil in H1 2018. We continue to expect EBITDA profitability for FY2017 ....